Table 3.
Univariable and multivariable analyses of clinicopathologic variables in relation to OS in patients with positive tumour markers before operation.
| Clinicopathologic characteristics | Univariable analysis | Multivariable analysis 1a | Multivariable analysis 2a | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.03 (1.01–1.06) | 0.01 | 1.04 (1.02–1.07) | 0.001 | 1.04 (1.02–1.07) | 0.001 |
| Sex | ||||||
| Male | Reference | |||||
| Female | 1.22 (0.71–2.11) | 0.48 | ||||
| BMI | 0.93 (0.87–0.99) | 0.03 | 0.93 (0.88–0.98) | 0.01 | 0.93 (0.88–0.98) | 0.004 |
| ASA score | ||||||
| 1 | Reference | |||||
| 2 | 1.32 (0.87–2.00) | 0.20 | ||||
| 3 | 1.98 (0.80–4.92) | 0.14 | ||||
| Tumour location | ||||||
| Upper | Reference | – | – | |||
| Middle | 0.97 (0.57–1.65) | 0.91 | – | 0.34 | – | 0.40 |
| Lower | 0.82 (0.48–1.38) | 0.45 | – | 0.77 | – | 0.82 |
| Mixed | 1.95 (1.15–3.33) | 0.01 | – | 0.06 | – | 0.05 |
| Tumour size | 1.01 (1.01–1.02) | <0.001 | 1.01 (1.00–1.02) | 0.02 | 1.01 (1.00–1.02) | 0.02 |
| Histologic type | ||||||
| Differentiated | Reference | |||||
| Undifferentiated | 1.08 (0.69–1.69) | 0.75 | ||||
| Vascular invasion | ||||||
| Negative | Reference | – | – | |||
| Positive | 1.82 (1.23–2.67) | 0.002 | – | 0.55 | – | 0.53 |
| Perineural invasion | ||||||
| Negative | Reference | – | – | |||
| Positive | 1.63 (1.09–2.44) | 0.02 | – | 0.11 | – | 0.09 |
| pT stage | ||||||
| T1 | Reference | – | – | |||
| T2 | 1.69 (0.15–18.60) | 0.67 | – | 0.72 | – | 0.69 |
| T3 | 5.44 (0.75–39.66) | 0.09 | – | 0.12 | – | 0.11 |
| T4a | 9.67 (1.34–69.82) | 0.03 | – | 0.06 | – | 0.05 |
| T4b | 14.50 (1.62–129.96) | 0.02 | – | 0.27 | – | 0.25 |
| pN stage | ||||||
| N0 | Reference | Reference | Reference | |||
| N1 | 2.12 (0.73–6.21) | 0.17 | 2.20 (0.75–6.45) | 0.15 | 2.17 (0.74–6.37) | 0.16 |
| N2 | 3.36 (1.25–9.00) | 0.02 | 4.14 (1.53–11.17) | 0.01 | 4.08 (1.51–11.01) | 0.01 |
| N3a | 3.87 (1.51–9.96) | 0.01 | 4.00 (1.54–10.35) | 0.004 | 3.85 (1.48–10.00) | 0.01 |
| N3b | 8.61 (3.37–21.95) | <0.001 | 7.88 (3.03–20.49) | <0.001 | 7.63 (2.93–19.89) | <0.001 |
| Adjuvant chemotherapy | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 0.59 (0.40–0.88) | 0.01 | 0.56 (0.37–0.84) | 0.01 | 0.56 (0.37–0.84) | 0.01 |
| Post-operative tumour marker response | ||||||
| Non-normalisation | Reference | Reference | ||||
| Normalisation | 0.61 (0.42–0.90) | 0.01 | 0.62 (0.41–0.92) | 0.02 | ||
| Number of positive tumour markers after surgery | ||||||
| 0 | Reference | Reference | ||||
| 1 | 1.54 (1.03–2.30) | 0.04 | 1.54 (1.02–2.34) | 0.04 | ||
| 2 | 2.50 (1.18–5.28) | 0.02 | 2.34 (1.07–5.10) | 0.03 | ||
aMultivariable analysis 1 included post-operative tumour markers response, excluding the number of positive tumour markers after treatment.
bMultivariable analysis 2 included the number of positive tumour markers after treatment, excluding post-operative tumour markers response.